Target Validation Information
TTD ID	T31309
Target Name	Apoptosis regulator Bcl-2 (BCL-2)
Type of Target	Successful
Drug Potency against Target	ABT-263	Drug Info	Ki = 0.5 nM	[6]
	MCI-186	Drug Info	IC50 = 270 nM	[5]
	2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide	Drug Info	IC50 = 7000 nM	[2]
	4,5-dibenzylbenzene-1,2-diol	Drug Info	IC50 = 4700 nM	[4]
	5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine	Drug Info	IC50 = 1600 nM	[1]
	ABT-737	Drug Info	Ki < 1 nM	[3]
	N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide	Drug Info	IC50 = 5000 nM	[2]
	QEDIIRNIARHLAQVGDSMDR	Drug Info	Ki = 11 nM	[2]
	TW-37	Drug Info	IC50 = 200 nM	[2]
References
REF 1	Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem. 2001 Dec 6;44(25):4313-24.
REF 2	Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42.
REF 3	Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem. 2007 Feb 22;50(4):641-62.
REF 4	Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic intervention. J Med Chem. 2010 May 27;53(10):3899-906.
REF 5	A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological ... J Pharmacol Exp Ther. 2005 Feb;312(2):472-81.
REF 6	BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov. 2008 Dec;7(12):989-1000.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.